Swiss Renewable Energy Stock News

Galderma Group (SWX:GALD) is back in focus after the U.S. FDA accepted its BLA resubmission for RelabotulinumtoxinA, a neuromodulator targeting adult frown lines and crow's feet in the aesthetics market. See our latest analysis for Galderma Group. The FDA update follows a mixed price pattern, with a 1-day share price return of 1.84% and a 7-day share price return of 1.63%, offset by a 30-day share price return decline of 9.56% and a year-to-date share price return decline of 6.68%. The 1-year...

Fresh equity placement puts Cosmo Pharmaceuticals in focus Cosmo Pharmaceuticals (SWX:COPN) has drawn attention after completing a private placement of 937,086 treasury shares, equal to 5.3% of its outstanding shares, with participation from Small Cap World Fund of the Capital Group. See our latest analysis for Cosmo Pharmaceuticals. At a share price of CHF117.0, Cosmo Pharmaceuticals has seen a 30 day share price return of 7.93% and a 90 day gain of 80.28%. Its 1 year total shareholder...

Amidst recent market volatility, European indices like the STOXX Europe 600 have shown resilience, buoyed by optimism surrounding the eurozone economy. As investors navigate this landscape, growth companies with high insider ownership often attract attention due to their potential alignment of interests between management and shareholders, a factor that can be particularly appealing in times of economic uncertainty.

There wouldn't be many who think Jungfraubahn Holding AG's ( VTX:JFN ) price-to-earnings (or "P/E") ratio of 22.7x is...

Why this new SMA launch matters for Partners Group Holding (SWX:PGHN) BlackRock and Partners Group Holding (SWX:PGHN) have introduced a multi alternatives separately managed account solution that packages private equity, private credit, and real assets access for financial advisors in a single, streamlined offering. See our latest analysis for Partners Group Holding. The new SMA launch comes after a weaker recent stretch for the shares, with a 7 day share price return showing a 6.49% decline...

INFICON guidance and what it might mean for shareholders INFICON Holding (SWX:IFCN) has drawn investor focus after issuing preliminary 2025 guidance that points to sales of about US$673.7 million and operating income of roughly US$112.3 million, compared with US$671.0 million and US$136.0 million in the prior year. See our latest analysis for INFICON Holding. The preliminary 2025 guidance, which points to broadly steady sales and lower operating income, lands after a strong 30-day share price...

If you have been wondering whether Roche Holding's current share price really lines up with its underlying worth, this article walks you through the key numbers that matter. Over the short term the stock has been relatively steady, with a 0.2% decline over the last 7 days. The 30 day, year to date and 1 year returns sit at 3.8%, 8.7% and 25.8% respectively, and the 3 year and 5 year figures are 41.4% and 33.3%. Recent coverage of Roche has focused on its position as a global healthcare group...

Executive reshuffle puts leadership focus back on core functions Flughafen Zürich (SWX:FHZN) has kicked off a broad management reshuffle, cutting its Executive Board from seven to six members and confirming the planned exit of Chief People & Communication Officer Manuela Staub in July 2026. See our latest analysis for Flughafen Zürich. At a share price of CHF249.6, Flughafen Zürich has seen a 4.44% 7 day share price return but a 4.22% 30 day share price decline. Its 1 year total shareholder...

The Swatch Group AG recently reported full-year 2025 results, with sales of CHF 6,280 million and net income of CHF 3 million, and affirmed an annual dividend of CHF 4.50 per share payable on May 19, 2026. The decision to maintain the dividend despite much weaker profitability offers a clear signal about management’s confidence in the group’s financial resilience and priorities for rewarding shareholders. We will now examine how the earnings weakness paired with the affirmed dividend shapes...

Why lucerastat’s new Phase 3 plan matters for Idorsia shareholders Idorsia (SWX:IDIA) has agreed with the US FDA on a Phase 3 registration program for lucerastat in Fabry disease, centered on kidney outcomes and backed by recently published MODIFY trial data. For you as an investor, this means lucerastat is moving from exploratory late stage data into a clearly defined path that is intended to support a potential marketing application, with health authority alignment already in place. See our...

Julius Bär Gruppe (SWX:BAER) has released its full year 2025 results, reporting net income of CHF 763.7 million and earnings per share lower than the prior year, a key focus for investors. See our latest analysis for Julius Bär Gruppe. At a share price of CHF66.82, Julius Bär Gruppe has delivered a 22.92% 90 day share price return and a 23.34% 1 year total shareholder return, suggesting momentum has been building even as earnings softened and the board proposed an unchanged CHF2.60 dividend...

Why Valiant Holding’s latest dividend and earnings matter Valiant Holding (SWX:VATN) has drawn fresh attention after reporting its 2025 full year results, alongside an annual dividend of CHF 6.00 per share. This gives investors clearer visibility on income and recent profitability. See our latest analysis for Valiant Holding. The earnings announcement and CHF 6.00 dividend appear to have been well received, with the share price at CHF 159.60 and a 90 day share price return of 19.64%,...

Earnings, dividend proposal and operating metrics at a glance Swiss Prime Site (SWX:SPSN) has paired its full year 2025 earnings release with a proposed dividend increase and fresh data on portfolio vacancy, acquisitions and asset management inflows, giving investors several angles to reassess the stock. For 2025, the company reported sales of CHF 456.81 million compared with CHF 463.50 million a year earlier. Net income came in at CHF 382.47 million versus CHF 360.25 million, while basic...

Why Givaudan’s latest earnings and dividend matter for shareholders Givaudan (SWX:GIVN) has put fresh numbers on the table, pairing its full year 2025 earnings release with an annual dividend announcement that gives investors clearer insight into both cash returns and recent business performance. See our latest analysis for Givaudan. The latest earnings and dividend announcement comes after a mixed share price stretch, with a 7 day share price return of 3.58% but a 1 year total shareholder...

Vontobel Holding (SWX:VONN) closed FY 2025 with second half revenue of CHF 741.7 million and basic EPS of CHF 2.94, while trailing 12 month revenue came in at CHF 1.43 billion with basic EPS of CHF 4.99, setting a clear benchmark for the latest reporting stretch. The company has seen revenue move from CHF 694.3 million and basic EPS of CHF 2.44 in 2024’s second half to CHF 741.7 million and CHF 2.94 respectively in 2025’s second half, with trailing net income of CHF 280.1 million framing a...

Logitech International (SWX:LOGN) has been in focus after reporting third quarter results and issuing guidance that points to higher expected sales for both the upcoming quarter and the full 2026 fiscal year. See our latest analysis for Logitech International. The recent third quarter results and higher sales guidance sit against a mixed share price backdrop, with a 1-week share price return of 5.58% but a 90-day share price return decline of 25.89%. At the same time, the 3-year total...

Why the latest ams-OSRAM (SWX:AMS) calls matter for shareholders Recent special and shareholder or analyst calls at ams-OSRAM (SWX:AMS) have put management’s messaging in focus, giving investors fresh commentary to weigh against the company’s current share performance and fundamentals. See our latest analysis for ams-OSRAM. At a share price of CHF8.24, ams-OSRAM’s recent 1-day share price return of 1.29% and 7-day return of 2.30% sit alongside a 90-day share price decline of 17.65% and a...

Novartis AG ( VTX:NOVN ) will increase its dividend from last year's comparable payment on the 12th of March to $3.70...

Q4 earnings and 2026 outlook ABB (SWX:ABBN) has drawn investor attention after reporting fourth quarter 2025 results alongside fresh 2026 guidance, providing new data points on profitability, demand expectations and management’s view of the order pipeline. For the fourth quarter, ABB reported revenue of US$9,052 million compared with US$7,996 million a year earlier. Net income was US$1,273 million versus US$987 million, with basic and diluted earnings per share from continuing operations at...

EMS-CHEMIE Holding (SWX:EMSN) has put fresh numbers on the table for FY 2025, with second half revenue of CHF 930.4 million, basic EPS of CHF 9.26 and net income of CHF 216.6 million, while trailing 12 month figures sit at CHF 1.95 billion of revenue, EPS of CHF 19.97 and net income of CHF 467 million. The company has seen revenue move from CHF 1,004.0 million and EPS of CHF 9.04 in the second half of 2024 to CHF 1,019.6 million and EPS of CHF 10.71 in the first half of 2025, before landing...

Q3 2026 results set the stage for a margin focused story LEM Holding (SWX:LEHN) has put fresh numbers on the table for Q3 2026, with revenue at CHF70.1 million, net income at CHF5.3 million and basic EPS of CHF4.64, while trailing 12 month figures show revenue of CHF294.4 million, net income of CHF8.4 million and EPS of CHF7.36 alongside forecast annual earnings growth of 45.9%. Over recent quarters the company has seen revenue move from CHF75.6 million in Q2 2025 to CHF76.0 million in Q4...

Why Vontobel’s latest earnings and dividend matter Vontobel Holding (SWX:VONN) has drawn fresh investor attention after reporting higher full year 2025 net income and earnings per share, together with asset under management growth and an affirmed annual dividend of CHF 3.00 per share. See our latest analysis for Vontobel Holding. The earnings and dividend announcement has coincided with a clear upswing in sentiment, with a 3.83% 1 day share price return and a 16.12% 90 day share price return...

Revenue growth event puts Compagnie Financière Tradition (SWX:CFT) in focus Compagnie Financière Tradition (SWX:CFT) caught investor attention after reporting 2025 consolidated revenue growth of 11.4% at constant exchange rates, with the fourth quarter advancing 11.7% on higher transaction volumes across asset classes and regions. See our latest analysis for Compagnie Financière Tradition. At a share price of CHF289.0, Compagnie Financière Tradition has had a mixed shorter term run, with a 1...

CEO transition puts SIG Group in focus SIG Group (SWX:SIGN) has confirmed that Mikko Keto will become CEO on 1 March 2026, while interim CEO Anne Erkens will return to her CFO role. This planned transition is being closely watched by shareholders. See our latest analysis for SIG Group. At a share price of CHF12.0, SIG Group has seen a 44.84% 90 day share price return. However, its 1 year total shareholder return of 36.91% indicates that longer term momentum has been weak and sentiment is...